pdsbiotech.comの競合サイトトップ10

nwbio.com

Development of effective immune therapies for cancer has long been a goal of the medical and scientific communities. The human immune system is very powerful, and also very complex: it is an “army” with many divisions and many different kinds of weapons. Dendritic cells are the “General” of this immune system “army.” They deliver the “marching orders” to the rest of the immune system agents which tell those agents what to attack. A diagram of some key agents and weapons of the immune system is set forth below: It has taken decades of research to identify the many different types of agents and weapons, to determine the relationships among them, and to determine how they work together to attack and defeat invaders such as bacteria, viruses and cancers. While the research was in process, early versions of immune therapies against cancers were tried, with mixed results and a number of failures. Over the course of the 1990s and 2000s, the first commercially successful category of immune agents to treat cancers emerged: drugs that consisted of individual antibodies, such as Avastin, Herceptin and Erbitux. These are considered passive immune therapies (in contrast to dendritic cell and T cell therapies which are considered active immune therapies). Antibodies are just one category of weapon in the overall immune “army,” and there are many, many kinds of individual antibodies within this category. Each antibody drug, such as Avastin, consists of just a single one of the many kinds of antibodies within this one category of immune system weapon. These drugs do not involve or make use of the numerous other important agents in the immune army, such as T cells, NK cells, and so on. Antibody drugs have been moderate medical successes and huge commercial successes. These drugs have delivered moderate extensions of patient survival compared with traditional chemotherapy drugs, with somewhat lesser (though still significant) toxicity. On this basis, these antibody drugs are achievin